Principal Financial Group Inc. trimmed its stake in shares of Carlisle Companies Incorporated (NYSE:CSL – Free Report) by 2.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned ...

Amid dangerously cold temperatures in the Kansas City region, the Community Services League’s Drop-In Center offers ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

CSL's latest dividend should be turning investors' heads... The post Everything you need to know about the latest CSL ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

Jonathan R. Collins, a director at $CSL, sold 1,050 shares of the company on 02-07-2025 for an estimated $366,702. We received data on the trade from a recent SEC ...

Hemgenix maintained factor IX levels at 37.4 IU/dL in year four, with a 90% reduction in annualized bleeding rates compared to baseline. At year four, 94% of patients remained off continuous ...